-5%
(Clopidogrel + Aspirin)
1. Acute Coronary Syndrome (ACS):
Clas® is indicated to reduce the risk of myocardial infarction (MI) and stroke in patients with:
- Non-ST-elevation ACS (NSTEMI and unstable angina)
- ST-elevation myocardial infarction (STEMI)
2. Secondary Prevention:
Used to lower the risk of MI and stroke in patients with a history of:
- Recent MI
- Recent stroke
- Established peripheral arterial disease (PAD)
Clopidogrel is a prodrug that irreversibly inhibits platelet aggregation by blocking ADP receptors (P2Y12) on platelets. Platelet inhibition begins within 2 hours of a single dose, with full effect achieved between days 3 and 7 on continuous dosing.
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 formation—a potent promoter of platelet aggregation and vasoconstriction.
Absorption: Clopidogrel is rapidly absorbed, with peak levels of its active metabolite occurring ~1 hour post-dose.
Bioavailability: At least 50% absorbed based on urinary metabolite excretion.
Protein Binding: Clopidogrel – 98%, Metabolite – 94% (non-saturable).
Metabolism: Primarily in the liver to inactive carboxylic acid derivative.
Excretion: ~50% in urine, ~46% in feces within 5 days.
Half-life: ~8 hours for the main metabolite.
Food does not significantly affect bioavailability.